Cargando…

Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples

Liquid chromatography-tandem mass spectrometry was used to analyze plasma proteins of volunteers (control) and patients with glioblastoma multiform (GBM). A database search was pre-set with a variable post-translational modification (PTM): phosphorylation, acetylation or ubiquitination. There were n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petushkova, Natalia A., Zgoda, Victor G., Pyatnitskiy, Mikhail A., Larina, Olesya V., Teryaeva, Nadezhda B., Potapov, Alexander A., Lisitsa, Andrey V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426747/ https://www.ncbi.nlm.nih.gov/pubmed/28493947 http://dx.doi.org/10.1371/journal.pone.0177427

Ejemplares similares

Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
por: Kiseleva, Olga I., et al.
Publicado: (2015)

Applying of Hierarchical Clustering to Analysis of Protein Patterns in the Human Cancer-Associated Liver
por: Petushkova, Natalia A., et al.
Publicado: (2014)

Protocol for Increasing the Sensitivity of MS-Based Protein Detection in Human Chorionic Villi
por: Shkrigunov, Timur, et al.
Publicado: (2022)

Comparative proteoinformatics revealed the essentials of SDS impact on HaCaT keratinocytes
por: Shkrigunov, Timur, et al.
Publicado: (2022)

The Size of the Human Proteome: The Width and Depth
por: Ponomarenko, Elena A., et al.
Publicado: (2016)

One-dimensional proteomic profiling of Danio rerio embryo vitellogenin to estimate quantum dot toxicity
por: Petushkova, Natalia A, et al.
Publicado: (2015)

Redox-Mediated Post-Translational Modifications of Proteolytic Enzymes and Their Role in Protease Functioning
por: Petushkova, Anastasiia I., et al.
Publicado: (2020)

Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma
por: Pyatnitskiy, Mikhail, et al.
Publicado: (2015)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
por: Füzéry, Anna K, et al.
Publicado: (2013)

Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells
por: Jones, Dylan, et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Does Proteomic Mirror Reflect Clinical Characteristics of Obesity?
por: Kiseleva, Olga I., et al.
Publicado: (2021)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles
por: Tucker Edmister, Sara, et al.
Publicado: (2022)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Correction: novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
por: Jiang, Pengfei, et al.
Publicado: (2014)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Procedure for Organizing a Post-FDA-approval Evaluation of Antidepressants
por: Alemi, Farrokh, et al.
Publicado: (2022)

Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules
por: Arasu, M.Valan, et al.
Publicado: (2023)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mp2qh7bpql7sjl31bu9itenkq5